- Universal Biosensors (UBI) signs an agreement with Peter MacCallum Cancer Centre for the supply of patient samples for UBI’s research initiative
- The agreement provides UBI with access to plasma samples collected from patients with colorectal, breast and prostate cancer
- Trial results will be used to develop Universal’s handheld point-of-care biosensor for Tn Antigen
- The trial is scheduled to begin during October, with results expected to become available during Q1 2022
- Universal Biosensors was up 1.11 per cent, trading at 91 cents at 1:42 pm AEST
Universal Biosensors (UBI) has penned an agreement with the Peter MacCallum Cancer Centre to supply cancer patient samples which will be used to develop and validate the performance of UBI’s handheld point-of-care cancer biosensor for Tn Antigen (Tn).
The agreement provides UBI with access to plasma samples collected from patients with colorectal, breast and prostate cancer as part of a Peter Mac research initiative. The samples will then be used to develop and validate the performance of Universal’s handheld point-of-care biosensor for Tn Antigen.
The aim of the trial is for the biosensor to accurately measure a patient’s cancer status via a more simple, cheap and frequent test. This could then potentially be used for early cancer diagnosis, disease staging and the monitoring of treatment effectiveness.
Trial results will then be used to confirm the presence of Tn in multiple cancer types.
“To be working with Peter Mac on the development of UBI’s handheld point-of-care cancer biosensor is very exciting for the company,” CEO of Universal Biosensors John Sharman said.
“The trial results and any subsequent development work will form part of any regulatory application to have Tn approved for sale by regulators around the world.”
The trial is scheduled to begin during October, with results expected to become available during Q1 2022.
Universal Biosensors was up 1.11 per cent, trading at 91 cents at 1:42 pm AEST.